{
  "main_header": {
    "sid": 10039665,
    "name": "Anthem Bioscienc",
    "stock_name": "Anthem Bioscienc",
    "full_name": "Anthem Biosciences Ltd",
    "name_url": "stocks-analysis/anthem-bioscienc",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "652.70",
    "chg": -8.8,
    "chgp": "-1.33%",
    "dir": -1,
    "prev_price": "661.50",
    "mcapval": "36,656.29 Cr",
    "mcap": "Large Cap",
    "scripcode": 544449,
    "symbol": "ANTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0CZ201020",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.22 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Anthem Bioscienc?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anthem-bioscienc-3683766",
        "imagepath": "",
        "date": "2025-11-09 22:50:20",
        "description": "Answer:\nThe historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nAnthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35..."
      }
    ],
    "total": 4,
    "sid": "10039665",
    "stock_news_url": "https://www.marketsmojo.com/news/anthem-biosciences-10039665"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "12-Nov-2025",
      "details": "Earnings Call Transcript for the financial result of quarter and half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Violation Under CompanyS Code Of Conduct To Regulate Monitor And Report Trading By Designated Persons As Required Under SEBI (Prohibition Of Insider Trading) Regulations 2015 (SEBI PIT Regulations)",
      "datetime": "11-Nov-2025",
      "details": "Intimation of Action Taken report for violation of Companys Code of Conduct on Insider Trading Regulation.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "10-Nov-2025",
      "details": "Newspaper Publication of Financial Result for the quarter and half year ended September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Anthem Bioscienc?

2025-11-09 22:50:20

Answer: The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,35...

Read More

View All News